promed pharmacy tirzepatide FDA confirms shortage is still over, gives compounders a grace period Tirzepatide: Injection Home Kit –

Wegovy GLP-1 receptor agonist only Average weight loss of approximately 1315% in clinical trials In head-to-head comparison, semaglutide achieved 13.7% mean weight loss at 72 weeks Often better tolerated for some individuals Zepbound Dual GIP and GLP-1 receptor agonist Average weight loss of 1521% , depending on dose 5 mg: ~15% 10 mg: ~19.5% 15 mg: ~21% In head-to-head comparison, tirzepatide achieved 20.2% mean weight loss at 72 weeks This does not mean Zepbound is universally superior

Excessive consumption of simple carbs can also contribute to weight gain or worsen insulin resistance

Patients who include resistance training in their routine often see improved body composition compared to those relying solely on cardio

8 weeks 56 syringes 1 syringe per day across 8 weeks

Goodman, A.L